AKRO is no longer listed. Its last trade on record was Dec 9, 2025. The price and figures on this page are from its last trading day and final filings, and are no longer updated.
| 4 | KBC Group NV | 2K | $74 | — | 0.002% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in AKRO — a direct measure of their conviction.
Institutions that fully closed their AKRO position in Q4 2025
| 105.31% |
| +1.93 pp |
| $1.94B |
| +27% |
| Q2 2024 | 151 | 11% | 103.38% | 2.21 pp | $1.53B | 10% |
| Q1 2024 | 169 | — | 105.59% | — | $1.71B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
0 institutions opened new positions in AKRO during Q4 2025, while 256 fully exited. 0 added to existing positions and 1 trimmed.
AKRO institutional ownership fell by 115.80 percentage points quarter-over-quarter, with a net change of -259 holders.
The top 10 institutions account for 100.0% of all reported 13F value in AKRO, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Akero Therapeutics, Inc. (AKRO) Institutional Ownership